Abstract
The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is arare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancercells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define pro-teomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the pro-tein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of post-translational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniquesallow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spec-trometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. Weintroduce the p53 protein as an illustration of the complexity of post-translational m odifications that may affect one highlyconnected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and statusof signal transduction systems of the malignancy.
Keywords: p53, AML, diagnosis, therapy, signaling networks, two-dimensional electrophoresis
Current Pharmaceutical Biotechnology
Title: Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia
Volume: 7 Issue: 3
Author(s): Nina Anensen, Ingvild Haaland, Clive D'Santos, Werner Van Belle and Bjorn Tore Gjertsen
Affiliation:
Keywords: p53, AML, diagnosis, therapy, signaling networks, two-dimensional electrophoresis
Abstract: The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is arare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancercells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define pro-teomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the pro-tein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of post-translational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniquesallow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spec-trometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. Weintroduce the p53 protein as an illustration of the complexity of post-translational m odifications that may affect one highlyconnected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and statusof signal transduction systems of the malignancy.
Export Options
About this article
Cite this article as:
Anensen Nina, Haaland Ingvild, D'Santos Clive, Werner Van Belle and Bjorn Tore Gjertsen , Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia, Current Pharmaceutical Biotechnology 2006; 7 (3) . https://dx.doi.org/10.2174/138920106777549731
DOI https://dx.doi.org/10.2174/138920106777549731 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Advances in the Discovery of Anthraquinone-Based Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?
Current Diabetes Reviews Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Current Targets for Anticancer Drug Discovery
Current Drug Targets Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry